Ticker HubNasdaq

AMGN

Amgen Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Latest price

$444.00+1.08%

As of Oct 26, 2026, 5:52 PM EDT · Market data by Massive

Market cap

$237.5B

Volume

2.1M

Previous close

$439.26

Day range

$439.50 – $449.80

Listed

Jun 17, 1983

Coverage

1 article

Price performance

Recent trading

5 trading days · 15-minute intervals · ET

Five-day open $427.66Latest interval $444.00

Newsroom

Latest AMGN coverage

BusinessCompanyApr 15, 2025

Amgen’s Obesity Moonshot: Could MariTide Be The Billion-Dollar Game-Changer?

As the global demand for weight-loss drugs skyrockets, Amgen has unveiled a strategic push into the space with its once-monthly injectable candidate, MariTide.

AMGN

Company overview

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 31.5K
Headquarters: THOUSAND OAKS, CA
CIK: 0000318154

Company website View advanced chart

SEC filings

No filing records are attached to this profile yet.

Browse EDGAR

Profile at a glance

Jun 17, 1983

Listed

31.5K

Employees

Market data may be delayed and is provided for informational purposes only. SmallCapsDaily content is not investment advice.